SIH Partners’s Sarepta Therapeutics SRPT Stock Holding History

SIH Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,867	Closed	-$374K	–	287
2025 Q1	$374K	Buy	+5,867	New	+$618K	0.01%	178

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

SIH Partners's SRPT Position: Q2 2025 in Review

SIH Partners sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 5,867 shares — an estimated $374K sold.

SIH Partners first reported a position in SRPT in Q1 2025 and held it in 1 quarter. The position peaked at $374K in Q1 2025. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

SIH Partners reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
SIH Partners sold 5,867 Sarepta Therapeutics shares in Q2 2025, an estimated $374K.
SIH Partners first reported a position in Sarepta Therapeutics in Q1 2025 and held it in 1 quarter.
SIH Partners's Sarepta Therapeutics position peaked at $374K in Q1 2025.
362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on SIH Partners's 13F filing for Q2 2025, filed 14 Aug 2025.